Gamma glutamyltranspeptidase activity and viral hepatitis in dialysis population

Fabrizio Fabrizi, A. F. de Vecchi, A. R. Qureshi, F. Aucella, G. Lunghi, A. Bruchfeld, S. Bisegna, S. Mangano, A. Limido, D. Vigilante, M. Forcella, P. delli Carri, Paul Martin

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Background: Numerous investigations have reported that viral hepatitis is associated with significant hepatocellular damage, as expressed by raised aminotransferases in serum, in dialysis population. However, scarce information exists on the activity of gamma glutamyltranspeptidase (GGTP) in dialysis patients with infection by hepatotropic viruses. Objectives: We measured serum GGTP values in a large cohort (n=757) of patients receiving long-term dialysis; healthy controls were also included. The relationship between GGTP values and a series of demographic, clinical, and biochemical parameters was analyzed. Methods: Serum GGTP levels were tested by spectrophotometry. A subset (n=333) of dialysis patients was tested by molecular technology (branched-chain DNA (bDNA) assay) to evaluate the relationship between serum GGTP and HCV viremia. A subgroup (n=78) of dialysis patients was analyzed by an ultrasound scan of gallbladder and biliary tract to assess the presence of gallstone disease. Multivariate analyses were made using regression models; serum GGTP values were included as a dependent variable. The usefulness of serum GGTP levels in detecting HBsAg and anti-HCV positivity was evaluated using receiver operating characteristics (ROC) curve analysis. Results: Univariate analysis showed that serum GGTP levels were significantly higher in HBsAg positive and/or anti-HCV positive patients than in HBsAg negative/anti-HCV negative patients on dialysis; 85.1±184.1 versus 25.86±23.9 IU/I (P=0.0001). The frequency of raised GGTP levels was 22.2% (41/184) among dialysis patients with chronic viral hepatitis. Multivariate analysis showed a significant and independent association between serum GGTP values and positive HBsAg (P=0.005) and anti-HCV antibody (P=0.0001) status. Mean GGTP values were significantly higher in study patients than controls, 32.32±60.02 versus 23.5±16.92 IU/L (P=0.01); however, no significant difference with regard to GGTP between study and healthy cohorts persisted after correction for age, gender, race, and viral markers. No relationship between gallstone disease and serum GGTP was found (NS). An independent and significant association (P=0.0291) between raised GGTP levels and detectable HCV RNA in serum was noted among patients tested by biology molecular techniques. ROC technology demonstrated that GGTP was equally useful for detecting HBV (P=0.0004) and HCV (P=0.0005) among dialysis patients. Conclusions: We found an independent and significant association between serum GGTP values and HBsAg and/or anti-HCV antibody in dialysis population. Twenty-two percent of dialysis patients with chronic viral hepatitis had elevated GGTP. No difference in GGTP between HBsAg- negative/anti-HCV-negative dialysis patients and healthy individuals was found. Routine testing for serum GGTP levels to assess liver disease induced by hepatotropic viruses or other agents in dialysis population is suggested.

Original languageEnglish
Pages (from-to)6-15
Number of pages10
JournalInternational Journal of Artificial Organs
Volume30
Issue number1
StatePublished - Jan 1 2007
Externally publishedYes

Fingerprint

Dialysis
Hepatitis
Hepatitis B Surface Antigens
Serum
Population
Hepatitis C Antibodies
Gallstones
Chronic Hepatitis
Viruses
Antibodies
ROC Curve
Branched DNA Signal Amplification Assay
Multivariate Analysis
Association reactions
Technology
Molecular biology
Spectrophotometry
Viremia
Biliary Tract
Virus Diseases

Keywords

  • Dialysis
  • Gamma glutamyltranspeptidase
  • Hepatitis B virus
  • Hepatitis C virus

ASJC Scopus subject areas

  • Biophysics

Cite this

Fabrizi, F., de Vecchi, A. F., Qureshi, A. R., Aucella, F., Lunghi, G., Bruchfeld, A., ... Martin, P. (2007). Gamma glutamyltranspeptidase activity and viral hepatitis in dialysis population. International Journal of Artificial Organs, 30(1), 6-15.

Gamma glutamyltranspeptidase activity and viral hepatitis in dialysis population. / Fabrizi, Fabrizio; de Vecchi, A. F.; Qureshi, A. R.; Aucella, F.; Lunghi, G.; Bruchfeld, A.; Bisegna, S.; Mangano, S.; Limido, A.; Vigilante, D.; Forcella, M.; delli Carri, P.; Martin, Paul.

In: International Journal of Artificial Organs, Vol. 30, No. 1, 01.01.2007, p. 6-15.

Research output: Contribution to journalArticle

Fabrizi, F, de Vecchi, AF, Qureshi, AR, Aucella, F, Lunghi, G, Bruchfeld, A, Bisegna, S, Mangano, S, Limido, A, Vigilante, D, Forcella, M, delli Carri, P & Martin, P 2007, 'Gamma glutamyltranspeptidase activity and viral hepatitis in dialysis population', International Journal of Artificial Organs, vol. 30, no. 1, pp. 6-15.
Fabrizi F, de Vecchi AF, Qureshi AR, Aucella F, Lunghi G, Bruchfeld A et al. Gamma glutamyltranspeptidase activity and viral hepatitis in dialysis population. International Journal of Artificial Organs. 2007 Jan 1;30(1):6-15.
Fabrizi, Fabrizio ; de Vecchi, A. F. ; Qureshi, A. R. ; Aucella, F. ; Lunghi, G. ; Bruchfeld, A. ; Bisegna, S. ; Mangano, S. ; Limido, A. ; Vigilante, D. ; Forcella, M. ; delli Carri, P. ; Martin, Paul. / Gamma glutamyltranspeptidase activity and viral hepatitis in dialysis population. In: International Journal of Artificial Organs. 2007 ; Vol. 30, No. 1. pp. 6-15.
@article{dcbaf9a98a714714add362dbb5c8ebdb,
title = "Gamma glutamyltranspeptidase activity and viral hepatitis in dialysis population",
abstract = "Background: Numerous investigations have reported that viral hepatitis is associated with significant hepatocellular damage, as expressed by raised aminotransferases in serum, in dialysis population. However, scarce information exists on the activity of gamma glutamyltranspeptidase (GGTP) in dialysis patients with infection by hepatotropic viruses. Objectives: We measured serum GGTP values in a large cohort (n=757) of patients receiving long-term dialysis; healthy controls were also included. The relationship between GGTP values and a series of demographic, clinical, and biochemical parameters was analyzed. Methods: Serum GGTP levels were tested by spectrophotometry. A subset (n=333) of dialysis patients was tested by molecular technology (branched-chain DNA (bDNA) assay) to evaluate the relationship between serum GGTP and HCV viremia. A subgroup (n=78) of dialysis patients was analyzed by an ultrasound scan of gallbladder and biliary tract to assess the presence of gallstone disease. Multivariate analyses were made using regression models; serum GGTP values were included as a dependent variable. The usefulness of serum GGTP levels in detecting HBsAg and anti-HCV positivity was evaluated using receiver operating characteristics (ROC) curve analysis. Results: Univariate analysis showed that serum GGTP levels were significantly higher in HBsAg positive and/or anti-HCV positive patients than in HBsAg negative/anti-HCV negative patients on dialysis; 85.1±184.1 versus 25.86±23.9 IU/I (P=0.0001). The frequency of raised GGTP levels was 22.2{\%} (41/184) among dialysis patients with chronic viral hepatitis. Multivariate analysis showed a significant and independent association between serum GGTP values and positive HBsAg (P=0.005) and anti-HCV antibody (P=0.0001) status. Mean GGTP values were significantly higher in study patients than controls, 32.32±60.02 versus 23.5±16.92 IU/L (P=0.01); however, no significant difference with regard to GGTP between study and healthy cohorts persisted after correction for age, gender, race, and viral markers. No relationship between gallstone disease and serum GGTP was found (NS). An independent and significant association (P=0.0291) between raised GGTP levels and detectable HCV RNA in serum was noted among patients tested by biology molecular techniques. ROC technology demonstrated that GGTP was equally useful for detecting HBV (P=0.0004) and HCV (P=0.0005) among dialysis patients. Conclusions: We found an independent and significant association between serum GGTP values and HBsAg and/or anti-HCV antibody in dialysis population. Twenty-two percent of dialysis patients with chronic viral hepatitis had elevated GGTP. No difference in GGTP between HBsAg- negative/anti-HCV-negative dialysis patients and healthy individuals was found. Routine testing for serum GGTP levels to assess liver disease induced by hepatotropic viruses or other agents in dialysis population is suggested.",
keywords = "Dialysis, Gamma glutamyltranspeptidase, Hepatitis B virus, Hepatitis C virus",
author = "Fabrizio Fabrizi and {de Vecchi}, {A. F.} and Qureshi, {A. R.} and F. Aucella and G. Lunghi and A. Bruchfeld and S. Bisegna and S. Mangano and A. Limido and D. Vigilante and M. Forcella and {delli Carri}, P. and Paul Martin",
year = "2007",
month = "1",
day = "1",
language = "English",
volume = "30",
pages = "6--15",
journal = "International Journal of Artificial Organs",
issn = "0391-3988",
publisher = "Wichtig Publishing",
number = "1",

}

TY - JOUR

T1 - Gamma glutamyltranspeptidase activity and viral hepatitis in dialysis population

AU - Fabrizi, Fabrizio

AU - de Vecchi, A. F.

AU - Qureshi, A. R.

AU - Aucella, F.

AU - Lunghi, G.

AU - Bruchfeld, A.

AU - Bisegna, S.

AU - Mangano, S.

AU - Limido, A.

AU - Vigilante, D.

AU - Forcella, M.

AU - delli Carri, P.

AU - Martin, Paul

PY - 2007/1/1

Y1 - 2007/1/1

N2 - Background: Numerous investigations have reported that viral hepatitis is associated with significant hepatocellular damage, as expressed by raised aminotransferases in serum, in dialysis population. However, scarce information exists on the activity of gamma glutamyltranspeptidase (GGTP) in dialysis patients with infection by hepatotropic viruses. Objectives: We measured serum GGTP values in a large cohort (n=757) of patients receiving long-term dialysis; healthy controls were also included. The relationship between GGTP values and a series of demographic, clinical, and biochemical parameters was analyzed. Methods: Serum GGTP levels were tested by spectrophotometry. A subset (n=333) of dialysis patients was tested by molecular technology (branched-chain DNA (bDNA) assay) to evaluate the relationship between serum GGTP and HCV viremia. A subgroup (n=78) of dialysis patients was analyzed by an ultrasound scan of gallbladder and biliary tract to assess the presence of gallstone disease. Multivariate analyses were made using regression models; serum GGTP values were included as a dependent variable. The usefulness of serum GGTP levels in detecting HBsAg and anti-HCV positivity was evaluated using receiver operating characteristics (ROC) curve analysis. Results: Univariate analysis showed that serum GGTP levels were significantly higher in HBsAg positive and/or anti-HCV positive patients than in HBsAg negative/anti-HCV negative patients on dialysis; 85.1±184.1 versus 25.86±23.9 IU/I (P=0.0001). The frequency of raised GGTP levels was 22.2% (41/184) among dialysis patients with chronic viral hepatitis. Multivariate analysis showed a significant and independent association between serum GGTP values and positive HBsAg (P=0.005) and anti-HCV antibody (P=0.0001) status. Mean GGTP values were significantly higher in study patients than controls, 32.32±60.02 versus 23.5±16.92 IU/L (P=0.01); however, no significant difference with regard to GGTP between study and healthy cohorts persisted after correction for age, gender, race, and viral markers. No relationship between gallstone disease and serum GGTP was found (NS). An independent and significant association (P=0.0291) between raised GGTP levels and detectable HCV RNA in serum was noted among patients tested by biology molecular techniques. ROC technology demonstrated that GGTP was equally useful for detecting HBV (P=0.0004) and HCV (P=0.0005) among dialysis patients. Conclusions: We found an independent and significant association between serum GGTP values and HBsAg and/or anti-HCV antibody in dialysis population. Twenty-two percent of dialysis patients with chronic viral hepatitis had elevated GGTP. No difference in GGTP between HBsAg- negative/anti-HCV-negative dialysis patients and healthy individuals was found. Routine testing for serum GGTP levels to assess liver disease induced by hepatotropic viruses or other agents in dialysis population is suggested.

AB - Background: Numerous investigations have reported that viral hepatitis is associated with significant hepatocellular damage, as expressed by raised aminotransferases in serum, in dialysis population. However, scarce information exists on the activity of gamma glutamyltranspeptidase (GGTP) in dialysis patients with infection by hepatotropic viruses. Objectives: We measured serum GGTP values in a large cohort (n=757) of patients receiving long-term dialysis; healthy controls were also included. The relationship between GGTP values and a series of demographic, clinical, and biochemical parameters was analyzed. Methods: Serum GGTP levels were tested by spectrophotometry. A subset (n=333) of dialysis patients was tested by molecular technology (branched-chain DNA (bDNA) assay) to evaluate the relationship between serum GGTP and HCV viremia. A subgroup (n=78) of dialysis patients was analyzed by an ultrasound scan of gallbladder and biliary tract to assess the presence of gallstone disease. Multivariate analyses were made using regression models; serum GGTP values were included as a dependent variable. The usefulness of serum GGTP levels in detecting HBsAg and anti-HCV positivity was evaluated using receiver operating characteristics (ROC) curve analysis. Results: Univariate analysis showed that serum GGTP levels were significantly higher in HBsAg positive and/or anti-HCV positive patients than in HBsAg negative/anti-HCV negative patients on dialysis; 85.1±184.1 versus 25.86±23.9 IU/I (P=0.0001). The frequency of raised GGTP levels was 22.2% (41/184) among dialysis patients with chronic viral hepatitis. Multivariate analysis showed a significant and independent association between serum GGTP values and positive HBsAg (P=0.005) and anti-HCV antibody (P=0.0001) status. Mean GGTP values were significantly higher in study patients than controls, 32.32±60.02 versus 23.5±16.92 IU/L (P=0.01); however, no significant difference with regard to GGTP between study and healthy cohorts persisted after correction for age, gender, race, and viral markers. No relationship between gallstone disease and serum GGTP was found (NS). An independent and significant association (P=0.0291) between raised GGTP levels and detectable HCV RNA in serum was noted among patients tested by biology molecular techniques. ROC technology demonstrated that GGTP was equally useful for detecting HBV (P=0.0004) and HCV (P=0.0005) among dialysis patients. Conclusions: We found an independent and significant association between serum GGTP values and HBsAg and/or anti-HCV antibody in dialysis population. Twenty-two percent of dialysis patients with chronic viral hepatitis had elevated GGTP. No difference in GGTP between HBsAg- negative/anti-HCV-negative dialysis patients and healthy individuals was found. Routine testing for serum GGTP levels to assess liver disease induced by hepatotropic viruses or other agents in dialysis population is suggested.

KW - Dialysis

KW - Gamma glutamyltranspeptidase

KW - Hepatitis B virus

KW - Hepatitis C virus

UR - http://www.scopus.com/inward/record.url?scp=34147107054&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34147107054&partnerID=8YFLogxK

M3 - Article

C2 - 17295188

AN - SCOPUS:34147107054

VL - 30

SP - 6

EP - 15

JO - International Journal of Artificial Organs

JF - International Journal of Artificial Organs

SN - 0391-3988

IS - 1

ER -